PD-1 inhibitors, such as nivolumab, pembrolizumab [10] and ipilimumab (anti-CTLA-4 or CD152), also block prototypical T-cell checkpoints and have revolutionized cancer therapy [11,12]. The gene discussed is CTLA4; the disease is cancer.